GENETIC SIGNATURES LIMITED (ASX: GSS)
Health care · News and insights
Price unavailable
Latest GSS announcements
Announcement Insights
Genetic Signatures Merger Terms Remain Unsettled as AGM Is Delayed
Genetic Signatures’ proposed merger with Microba has remained contested, with shareholders rejecting three resolutions at the 28 October EGM and BCAL Diagnostics opposing the proposed terms. On 12 November, the company delayed its AGM to continue negotiating commercial terms; on 16 November it requested a trading halt ahead of an update on proposed material changes to the merger terms.
Updated 16 Nov 2026, 09:34 AM Sydney time
Sources
Trading HaltPostponement of AGM & Further Addendum to the Notice of AGM3X Initial Directors Interest NoticeNotification regarding unquoted securities - GSSResults of 2026 EGM and Appointment of DirectorBDX: BCAL Welcomes Dr John Melki's Appointment to GSS BoardComments
2026-11-16 · Health care
GSS: $0.072 +0.00% · MC: $16M
Genetic Signatures requested a trading halt pending an announcement about proposed material changes to the terms of its proposed merger with Microba Life Sciences. The halt is expected to last until the announcement or the start of trading on Wednesday, whichever comes first.
Updated 2026-11-16 09:26
Sources
Trading HaltComments
2026-11-12 · Health care
GSS: $0.072 +0.00% · MC: $16M
Genetic Signatures has postponed its AGM to allow more time to negotiate and finalise commercial terms of its proposed merger with Microba Life Sciences. The company has withdrawn the resolution for Dr Jenny Harry’s re-election; she will remain a director, while Anne Lockwood will stand for re-election.
Updated 2026-11-12 19:27
Sources
Postponement of AGM & Further Addendum to the Notice of AGMComments
2026-11-02 · Health care
GSS: $0.078 +0.00% · MC: $16M
Genetic Signatures issued long-term incentive rights under its employee plan, including rights to key management personnel, and newly appointed director John Robert Melki disclosed an indirect interest in shares held through HSBC Custody Nominees. The company’s 28 October meeting approved Melki’s appointment, while three other resolutions were rejected.
Updated 2026-11-02 14:42
Sources
3X Initial Directors Interest NoticeNotification regarding unquoted securities - GSSComments
2026-10-28 · Health care
GSS: $0.079 +5.33% · MC: $16M
Genetic Signatures shareholders appointed John Melki as a non-executive director at an extraordinary meeting, while rejecting three other resolutions. BCAL Diagnostics welcomed the appointment but reiterated its opposition to Genetic Signatures’ proposed merger with Microba, saying the terms do not adequately reflect Genetic Signatures’ contribution and calling for more information and an independent assessment for its shareholders.
Updated 2026-10-28 16:10
Sources
Results of 2026 EGM and Appointment of DirectorBDX: BCAL Welcomes Dr John Melki's Appointment to GSS BoardComments
Comments